Edition:
United States

BioScrip Inc (BIOS.O)

BIOS.O on Nasdaq

2.43USD
20 Oct 2017
Change (% chg)

$-0.01 (-0.41%)
Prev Close
$2.44
Open
$2.49
Day's High
$2.53
Day's Low
$2.42
Volume
471,380
Avg. Vol
1,356,638
52-wk High
$3.39
52-wk Low
$0.98

Chart for

About

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates... (more)

Overall

Beta: 0.23
Market Cap(Mil.): $309.76
Shares Outstanding(Mil.): 127.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 29.48 16.52
EPS (TTM): -- -- --
ROI: -- 6.48 11.32
ROE: -- 10.22 15.18

BRIEF-BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis

* BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA Source text for Eikon: Further company coverage:

Oct 05 2017

BRIEF-Coliseum Capital reports 14.6 pct stake in Bioscrip

* Coliseum Capital Management LLC reports 14.6 percent stake in Bioscrip Inc as of September 7, 2017 - SEC filing‍​

Sep 08 2017

BRIEF-BioScrip qtrly loss per share $0.26

* Q2 revenue $218.1 million versus I/B/E/S view $220.2 million

Aug 08 2017

BRIEF-Ares Management reports 9.2 pct stake in Bioscrip

* Ares Management reports 9.2 pct stake in Bioscrip as of June 29 - SEC filing

Jul 10 2017

BRIEF-BioScrip announces new senior note facilities

* BioScrip Inc - under agreement, company entered into a $200 million first lien note facility and a $110 million second lien note facility

Jun 29 2017

BRIEF-Bioscrip provides update on Unitedhealthcare contract

* Bioscrip Inc - ‍reached an agreement to continue to provide certain core product lines to unitedhealthcare beyond September 30, 2017​

May 30 2017

BRIEF-Bioscrip reports first quarter 2017 financial results

* Q1 revenue $217.8 million versus I/B/E/S view $229.7 million

May 04 2017

Earnings vs. Estimates